Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
Here's Why Agios Pharmaceuticals Crashed 23% Today
SG Americas Securities LLC Increases Position in Agios Pharmaceuticals, Inc. $AGIO
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A.
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
ArrowMark Colorado Holdings LLC Has $27.29 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharma Stock: A Buy After FDA Approves Aqvesme